Cargando…

Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs

Photoactivatable Pt(IV) anticancer prodrugs with the structure of [Pt(IV)(N(1))(N(2))(L(1))(L(2))(A(1))(A(2))], where N(1) and N(2) are non-leaving nitrogen donor ligands, L(1) and L(2) are leaving ligands, and A(1) and A(2) are axial ligands, have attracted increasing attention due to their promisi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Jingjing, Ding, Weize, Zhu, Xingfan, Li, Bingbing, Zeng, Fangang, Wu, Kui, Wu, Xiaoqin, Wang, Fuyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218644/ https://www.ncbi.nlm.nih.gov/pubmed/35755267 http://dx.doi.org/10.3389/fchem.2022.876410

Ejemplares similares

Photoactivatable Cell-Selective Dinuclear trans-Diazidoplatinum(IV) Anticancer Prodrugs
por: Shi, Huayun, et al.
Publicado: (2018)

Single-Cell Chemistry of Photoactivatable Platinum Anticancer Complexes
por: Bolitho, Elizabeth M., et al.
Publicado: (2021)

Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity
por: Khoury, Aleen, et al.
Publicado: (2022)

Photoactivatable platinum anticancer complex can generate tryptophan radicals
por: Vallotto, Claudio, et al.
Publicado: (2018)

Tumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs
por: Kastner, Alexander, et al.
Publicado: (2023)

Photoactivatable Platinum-Based Anticancer Drugs: Mode of Photoactivation and Mechanism of Action
por: Dai, Ziwen, et al.
Publicado: (2020)

Induction of targeted necrosis with HER2-targeted platinum(iv) anticancer prodrugs
por: Wong, Daniel Yuan Qiang, et al.
Publicado: (2015)

Improving the anticancer activity of platinum(iv) prodrugs using a dual-targeting strategy with a dichloroacetate axial ligand
por: Liu, Fengfan, et al.
Publicado: (2019)

Potent Chlorambucil-Platinum(IV) Prodrugs
por: Aputen, Angelico D., et al.
Publicado: (2022)

Photoactivatable Caged Prodrugs of VEGFR-2 Kinase Inhibitors
por: Pinchuk, Boris, et al.
Publicado: (2016)

Repurposing Platinum(IV) Prodrugs to Modulate Mitochondrial Metabolism
por: Zacharioudakis, Emmanouil, et al.
Publicado: (2023)

Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib
por: Li, Jiaguo, et al.
Publicado: (2020)

Structure–Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands
por: Fronik, Philipp, et al.
Publicado: (2021)

Cell-permeable lanthanide–platinum(iv) anti-cancer prodrugs
por: Yao, Kezi, et al.
Publicado: (2021)

Self-assembly nanoplatform of platinum (Ⅳ) prodrug for enhanced ovarian cancer therapy
por: Ma, Xiao, et al.
Publicado: (2023)

Pt(IV) Prodrugs with NSAIDs as Axial Ligands
por: Spector, Daniil, et al.
Publicado: (2021)

Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo
por: Schueffl, Hemma, et al.
Publicado: (2021)

A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance
por: Fronik, Philipp, et al.
Publicado: (2022)

Versatile Platinum(IV) Prodrugs of Naproxen and Acemetacin as Chemo-Anti-Inflammatory Agents
por: Aputen, Angelico D., et al.
Publicado: (2023)

Platinum(II) Terpyridine Anticancer Complexes Possessing Multiple Mode of DNA Interaction and EGFR Inhibiting Activity
por: Li, Chaoyang, et al.
Publicado: (2020)

Cetuximab-decorated and NIR-activated Nanoparticles Based on Platinum(IV)-prodrug: Preparation, Characterization and In-vitro Anticancer Activity in Epidermoid Carcinoma Cells
por: Wang, Yu, et al.
Publicado: (2021)

De Novo Generation of Singlet Oxygen and Ammine Ligands by Photoactivation of a Platinum Anticancer Complex**
por: Zhao, Yao, et al.
Publicado: (2013)

Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands
por: Li, Xuejiao, et al.
Publicado: (2018)

Exploring the Impact of Head Group Modifications on the Anticancer Activities of Fatty-Acid-like Platinum(IV) Prodrugs: A Structure–Activity Relationship Study
por: Kshetri, Man, et al.
Publicado: (2023)

Glutathione boosting the cytotoxicity of a magnetic platinum(iv) nano-prodrug in tumor cells
por: Zhu, Zhenzhu, et al.
Publicado: (2016)

pH/redox sensitive nanoparticles with platinum(iv) prodrugs and doxorubicin enhance chemotherapy in ovarian cancer
por: Zhang, Guyu, et al.
Publicado: (2019)

Potent Platinum(IV) Prodrugs That Incorporate a Biotin Moiety to Selectively Target Cancer Cells
por: Khoury, Aleen, et al.
Publicado: (2022)

In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent
por: Olszewski, Ulrike, et al.
Publicado: (2009)

Axial functionalisation of photoactive diazido platinum(iv) anticancer complexes
por: Shi, Huayun, et al.
Publicado: (2020)

Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions
por: Savino, Salvatore, et al.
Publicado: (2018)

The impact of whole human blood on the kinetic inertness of platinum(iv) prodrugs – an HPLC-ICP-MS study
por: Theiner, Sarah, et al.
Publicado: (2018)

Oxaliplatin-Based Platinum(IV) Prodrug Bearing Toll-like Receptor 7 Agonist for Enhanced Immunochemotherapy
por: Tang, Li, et al.
Publicado: (2019)

A visible-light photoactivatable di-nuclear Pt(IV) triazolato azido complex
por: Yao, Kezi, et al.
Publicado: (2019)

Potential Anticancer Activities and Catalytic Oxidation Efficiency of Platinum(IV) Complex
por: El-bendary, Mohamed M., et al.
Publicado: (2022)

Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer
por: Zhang, Rongrong, et al.
Publicado: (2017)

Photoactivatable drugs for nicotinic optopharmacology
por: Banala, Sambashiva, et al.
Publicado: (2018)

Multi-scale imaging of anticancer platinum(iv) compounds in murine tumor and kidney
por: Legin, A. A., et al.
Publicado: (2016)

Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug–Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines
por: Barth, Marie-Christin, et al.
Publicado: (2023)

Combination of IDO inhibitors and platinum(IV) prodrugs reverses low immune responses to enhance cancer chemotherapy and immunotherapy for osteosarcoma
por: Xiang, Dongquan, et al.
Publicado: (2023)

In situ oxidative polymerization of platinum(iv) prodrugs in pore-confined spaces of CaCO(3) nanoparticles for cancer chemoimmunotherapy
por: Wei, Fangmian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jathjo48hg7i5pafp92r98kjlk